FLORIKAN-E.S.A., LLC – Trademark Portfolio

Entity Type: 16

FLORIKAN-E.S.A., LLC holds 8 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 7 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 2 Nice Classification classes. Currently, 4 trademarks are registered. Notable registered marks include FLORIKAN and FLORIKAN CRF. The owner is based in SARASOTA, FL.

1579 BARBER ROAD

SARASOTA, FL 34240

8 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

Trademark Classifications

FLORIKAN-E.S.A., LLC's trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.

1
Chemicals (7 filings)

Chemical products for industry, science, photography, agriculture, horticulture and forestry

42
Computer & Scientific (1 filing)

Scientific and technological services; industrial analysis and research services

Frequently Asked Questions

How many trademarks does FLORIKAN-E.S.A., LLC have?

FLORIKAN-E.S.A., LLC has 8 U.S. trademarks filed with the USPTO. Of these, 4 registered, 1 abandoned, 3 cancelled.

What trademark classes does FLORIKAN-E.S.A., LLC file in?

FLORIKAN-E.S.A., LLC files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.

What are FLORIKAN-E.S.A., LLC's most well-known trademarks?

FLORIKAN-E.S.A., LLC's registered trademark portfolio includes well-known marks such as FLORIKAN and FLORIKAN CRF. These are among 4 currently registered trademarks in the portfolio.

What is FLORIKAN-E.S.A., LLC's trademark registration success rate?

FLORIKAN-E.S.A., LLC has a 50% trademark registration rate, with 4 out of 8 resolved applications resulting in successful registration. Currently, 0 applications are pending review.